The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued two notable decisions on orphan drugs, backing Minoryx’s cALD therapy while rejecting a separate proposal for Niemann-Pick disease type C. In a process that included multiple positive opinions, Minoryx’s cALD program won CHMP support after prior regulatory hurdles.